Amgen Optimistic About Growth, Despite Denosumab Biosimilars, Potential Tariffs

MariTide Phase II Obesity Details Planned For ADA

 
• By Mandy Jackson
  
Repatha, Evenity and eight other Amgen products had double- or triple-digit growth in 2024 (Shutterstock)

More from Earnings

More from Scrip